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The tumor suppressor p53 is regulated in part by binding to cellular
proteins. We used p53 as bait in the yeast two-hybrid system and
isolated homeodomain-interacting protein kinase 1 (HIPK1) as a
p53-binding protein. Deletion analysis showed that amino acids
100–370 of p53 and amino acids 885-1093 of HIPK1 were sufficient
for HIPK1–p53 interaction. HIPK1 was capable of autophosphory-
lation and specific serine phosphorylation of p53. The HIPK1 gene
was highly expressed in human breast cancer cell lines and onco-
genically transformed mouse embryonic fibroblasts. HIPK1 was
localized to human chromosome band 1p13, a site frequently
altered in cancers. Gene-targeted HIPK1 mice were grossly
normal but oncogenically transformed HIPK1  mouse embry-
onic fibroblasts exhibited reduced transcription of Mdm2 and were
more susceptible than transformed HIPK1 cells to apoptosis
induced by DNA damage. Carcinogen-treated HIPK1  mice
developed fewer and smaller skin tumors than HIPK1 mice.
HIPK1 may thus play a role in tumorigenesis, perhaps by means of
the regulation of p53 andor Mdm2.
The most frequently mutated gene associated with humancancers is p53 (1, 2). In response to cellular stresses such as
DNA damage and oncogene expression, p53 promotes cell-cycle
arrest or apoptosis (3, 4). p53 stabilization and activity are
regulated by conformational changes (3) and posttranslational
modification by phosphorylation (5). However, the kinase(s)
relevant for phosphorylation of p53 in vivo remain obscure. p53
activity is also regulated by interaction with cellular molecules
such as the oncogenic protein Mdm2 (2). Overexpression of
Mdm-2 in certain tumors results in the inactivation and degra-
dation of p53 (6–10). We set out to identify proteins that interact
with p53 and to examine the expression of these molecules in
transformed cells. We isolated the p53-binding kinase home-
odomain-interacting protein kinase 1 (HIPK1), previously iden-
tified as a homeodomain-interacting protein (11), and analyzed
p53–HIPK1 interaction by various means. The physiological
functions of HIPK1 were characterized by using gene-targeted
HIPK1-deficient mice. Our in vivo and in vitro characterizations
of HIPK1 suggest that HIPK1 is a modulator of p53 activity that
can promote oncogenesis.
Methods
Yeast Two-Hybrid Screening. A human p53 cDNA (amino acids
71–393; ref. 12) was subcloned in-frame into pGBT9 (GAL4
DNA-binding domain vector) and used to screen cDNA libraries
constructed by using pGAD424 (GAL4-activation-domain plas-
mid; ref. 13) in yeast Y2H strain SFY526. The libraries were
derived from rat embryo fibroblasts transformed with E1A 
Ras  mutant p53 R273H, and a breast cancer cell line.
-Galactosidase activities were measured by using the Galacto-
Light reporter assay kit (Tropix, Bedford, MA). The cDNA
plasmids from -galactosidase-positive yeast were rescued, re-
tested in yeast, and sequenced.
Interaction of HIPK1 with p53 in 293 Cells. The SalINotI HIPK1
fragment corresponding to amino acids 678-1149 was ligated
in-frame with either a Myc tag in the pRcCMV vector or a His
tag in the pEBVHis vector (Invitrogen). Human 293 cells
expressing endogenous p53 were transfected with the myc-
HIPK1 expression plasmid by using Lipofectamine (GIBCO
BRL). After 48 h, lysate supernatants were immunoprecipitated
by using anti-p53 antibody (DO-1; Santa Cruz Biotechnology)
conjugated to agarose beads. The supernatants were immuno-
blotted by using anti-myc antibody (Oncogene Science) and
visualized by enhanced chemiluminescence (ECL; Amersham
Biosciences).
Isolation of Full-Length Human and Mouse HIPK1 cDNAs and p53–
HIPK1 Interaction Domains. Using the rat cDNA as a probe, we
cloned full-length human HIPK1 (1210 aa) was cloned from a
skeletal muscle Stretch Plus lambda gt11 library (BD Biosciences
Clontech), and full-length mouse HIPK1 was cloned from the
RNA of transformed mouse embryonic fibroblasts (MEFs).
Deletion mutations of the p53 and HIPK1 genes were created by
using standard PCR protocols and were used to map their
interaction domains. p53 deletions were cloned into EcoRISalI
sites in pGBT9 and HIPK1 deletions were cloned into EcoRI
SalI sites of pGAD424. The DNA sequences were confirmed and
the mutants were tested in Y2H.
Northern Blot Analyses. Tissue distribution of WT HIPK1 expres-
sion was examined by using a commercial human tissue RNA
blot (BD Biosciences Clontech). For all other Northern blots, 20
g of total RNA isolated from primary or transformed cells of
mouse or human origin by the TRIzol method (GIBCOBRL)
was used. Blots were prepared by using standard protocols
and hybridized to the following probes: full-length human or
mouse HIPK1 cDNAs; mdm-2 cDNA (base pairs 562-1197);
full-length mouse p21 cDNA; and mouse TSP-1 cDNA (base
pairs 941-2092).
Kinase Assays of HIPK1 Expressed in COS Cells. pcDNA3.1DNAZeo
plasmids (Invitrogen) containing the control HA sequence or
the HA-tagged full-length murine HIPK1 cDNA were trans-
fected into COS cells by using Lipofectamine-plus reagents
(GIBCOBRL). Cell lysates were immunoprecipitated with
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anti-HA antibody (Invitrogen), suspended in kinase buffer (40
mM Hepes10 mM MgCl23 mM MnCl2) with 1 g of GST-
fused p53 protein (Santa Cruz Biotechnology), and incubated
with 10 M [-32P]ATP for 30 min. The mixture was boiled,
resolved by electrophoresis, and visualized by autoradiography.
Comparative Phosphopeptide Analysis of p53. Transformed
HIPK1 and  MEFs were labeled in 150-mm dishes for
3 h with 5 mCi (1 Ci 37 GBq) of [32P]orthophosphate. p53 was
isolated from cell extracts by immunoprecipitation with anti-p53
Ab-4 antibody (Oncogene Science). Immunoprecipitated pro-
teins were fractionated by SDSPAGE and subjected to trypsin
digestion and phosphopeptide and phosphoamino acid analysis
as described (14).
Generation of HIPK1 Mice. Genomic clones of HIPK1 DNA
were isolated from a 129J mouse library by using the rat cDNA
probe. A targeting vector was constructed by using pBluescript
II KS() (Stratagene), which replaced 2.7 kb of genomic DNA
containing the first exon of HIPK1 (encoding the putative kinase
domain) with a neomycin-resistance cassette inserted in sense
orientation to HIPK1 transcription. The targeting vector was
electroporated into E14K embryonic stem (ES) cells. After G418
selection (GIBCOBRL), homologous recombinants were iden-
tified by PCR and confirmed by Southern blotting. Four clones
heterozygous for the targeted mutation were injected into
3.5-day-old C57BL6 blastocysts and transferred into pseudo-
pregnant foster mothers. Chimeric mice were crossed into
C57BL6 mice to generate heterozygous mice, which were
intercrossed to produce HIPK1 mice. Genotypes were
confirmed by Southern blotting of tail DNA. For the generation
of HIPK1 ES cell lines, G418-resistant HIPK1 ES
clones were cultured at an increased concentration of G418 (1.2
mgml) and analyzed by Southern blotting.
Retrovirus-Mediated Gene Transfer. Ectopic retroviruses were pro-
duced by using the Phoenix packaging line (generously provided
by G. Nolan, Stanford University, Stanford, CA). The retroviral
vectors were pLPC-12S, which coexpresses 12S E1A cDNA with
puromycin phosphotransferase, and pWZL-RasCD8, which
coexpresses human H-Ras V12 cDNA with the CD8 cell-surface
marker. WT and HIPK1 MEFs were infected first with
pLPC-12S and cells were selected in medium containing 2.5
gml puromycin (Sigma). Puromycin-resistant cells were then
infected with pWZL-RasCD8 and transformed cells were re-
covered with magnetic beads conjugated to anti-CD8 (Dynal,
Great Neck, NY).
Colony Transformation, Apoptosis, and Reintroduction of HIPK1. For
colony transformation assays, cells were suspended in 0.4%
low-melting agarose in DMEM containing 10% FCS and plated
on solidified 0.53% agarose at 1  103 cells per well on six-well
plates. Colony numbers were scored after 10 days. For apoptosis
assays, transformed MEFs (1  105 per well) were plated in
six-well plates and treated for 24 h with doxorubicin (0.2 gml),
etoposide (1 M), or -irradiation (20 Gy). Cell viability was
determined by negative staining for the vital dye 7-aminoacti-
nomycin D followed by flow cytometry. For the reintroduction
of HIPK1 into HIPK1-transformed MEFs, cells were elec-
troporated with pcDNA3.1Zeo vector containing HIPK1
cDNA or the control hemagglutinin (HA) sequence and selected
in medium containing 0.3 mgml zeocin (Invitrogen).
Luciferase Assays and Western Blots. HIPK1- and -
transformed MEFs (1  106 cells per 10-cm dish) were tran-
siently cotransfected by electroporation with 5 g of Mdm2-
luciferase reporter plasmid plus 5 g of GFP plasmid (for
normalization of transfection efficiency). The Mdm2-luciferase
reporter plasmid contained the intronic Mdm2 ApaINsiI frag-
ment, which has two p53-binding motifs (15). The p21 luciferase
reporter plasmid contained 20 base pairs of the 5 p53 response
element of the human p21 gene (16). Luciferase activities were
determined 48 h after electroporation by the Luciferase Assay
system (Promega). Western blots were performed by using
standard protocols. Antibodies used were as follows: CM5
(Novocastra, Newcastle upon Tyne, U.K.) for p53; 2A10, pro-
vided by G. Zambetti, St. Jude Children’s Research Hospital,
Memphis, TN, for Mdm2; and anti--actin (Sigma). For evalu-
ation of p53 status, cell lysates were immunoprecipitated with
either PAb240 (anti-mutant p53; Santa Cruz Biotechnology) or
PAb246 (anti-WT p53; Santa Cruz Biotechnology), and immu-
noblotted with biotinylated PAb240 antibody (Oncogene Re-
search Products, San Diego).
(7,12-Dimethylbenz[a]anthracene) DMBA-Induced Skin Papilloma For-
mation. Two independent experiments were carried out. Exper-
iment 1 involved 8 HIPK1, 11 HIPK1, and 13
HIPK1mice, whereas experiment 2 involved 11 HIPK1
and 10 HIPK1 mice. The backs of 8-week-old mice were
shaved and painted with 10 g of DMBA (Sigma) in 0.2 ml of
acetone once a week for a period of 14 (experiment 1) or 17
weeks (experiment 2). Scoring for tumors was done once a week.
All mice were killed at 14 (experiment 1) or 17 weeks (experi-
ment 2) and representative organs (including skin) were exam-
ined histopathologically.
Results
When human WT p53 (amino acids 71–393) was used as bait
in a yeast two-hybrid assay (13) to screen a transformed rat-
embryonic-fibroblast cDNA library, a previously undescribed
kinase, HIPK1, was identified. Human 293 cells expressing
endogenous p53 were then transfected with a plasmid express-
ing a Myc-tagged HIPK1 fusion protein expressing amino
acids 678-1149 of human HIPK1, or with empty Myc-vector. In
immunoprecipitation experiments, a distinct protein band at 65
kDa was observed only in extracts of cells transfected with the
Myc-HIPK1 vector (Fig. 1A), indicating that HIPK1 can form a
stable intracellular complex with p53. Sequence analysis of the
full-length human HIPK1 cDNA showed that the HIPK1 protein
contains a putative serine-threonine kinase domain (17), and in
situ hybridization revealed that HIPK1 localizes to human chro-
mosome band 1p13, a region frequently altered in human breast
cancers (ref. 18; data not shown). Deletion analyses using yeast
two-hybrid assays showed that a 271-aa region of p53 spanning
amino acids 100–370 was sufficient for association with HIPK1
(Fig. 1B). This region overlaps the p53 domain known to be
involved in binding to specific DNA sequences but does not
include the p53-transactivation domain or the nonspecific DNA-
interaction domain (12). A region of HIPK1 spanning amino
acids 885-1093 (which does not include the kinase domain) was
found to be necessary for binding to p53 (Fig. 1C).
High-stringency Northern blot analysis revealed that the 9
kb of HIPK1 mRNA was expressed in heart, brain, placenta,
skeletal muscle, and pancreas (Fig. 2A). Interestingly, in 12 of 14
human breast cancer cell lines tested, HIPK1 mRNA was ele-
vated, compared with levels in normal mammary epithelial cells
and a nontumorigenic cell line (Fig. 2B). In two of these cell lines
(MCF7 and BT20-T), HIPK1 was expressed at10 times control
levels, suggesting that HIPK1 might be an oncogene.
We next investigated whether HIPK1 phosphorylated p53.
HIPK1 protein immunoprecipitated from lysates of COS cells in
which murine HIPK1 was transiently expressed were subjected
to in vitro kinase assays using p53 as substrate. The results
showed that, in vitro, HIPK1 was able to phosphorylate itself, but
not p53 (Fig. 3A). Because the phosphorylation of p53 by HIPK1
might require a cellular context, we looked at the phosphoryla-
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tion status of p53 in transformed MEFs generated from either
HIPK1 or HIPK1 mice (see below). After labeling of
MEFs with 32P in vivo, lysates were immunoprecipitated with
anti-p53 antibody and the electrophoresed p53 band was isolated
and subjected to tryptic phosphopeptide analysis. The presence
of HIPK1 led to the appearance of a unique phosphopeptide
spot that was absent in cells lacking HIPK1 (Fig. 3B). Phos-
phoamino acid analysis of this spot revealed phospho-serine
exclusively (Fig. 3 B Inset). The relative mobility of the HIPK1-
induced phosphopeptide was consistent with its being the mul-
tiply phosphorylated N-terminal 27-aa tryptic peptide of p53
identified in previous reports (19, 20). Thus, HIPK1 can induce
serine phosphorylation of p53 in vivo.
To determine the physiological role of HIPK1, HIPK1-
deficient mice were created by conventional gene targeting (see
Methods). The genotypes of HIPK1 and HIPK1 mice
were confirmed by Southern analysis and deletion of HIPK1 was
confirmed by Northern analysis of RNA from primary MEFs
and ES cells (data not shown). HIPK1mice were born at the
expected Mendelian frequency, displayed no gross abnormalities
of growth or development, and were fertile. No spontaneous
tumors were observed in HIPK1 mice over a 1-yr period.
To examine the role of HIPK1 in oncogenesis, E1A and H-Ras
oncogenes (E1ARas) were introduced into HIPK1 and
HIPK1 primary MEFs by retroviral gene transfer (21).
Cellular transformation was achieved in both cases, as deter-
mined by tumor formation in nude mice (data not shown).
Expression of HIPK1 was increased in four independent clones
of E1ARas-transformed HIPK1 MEFs compared with
nontransformed WT MEFs (Fig. 4A). In colony-formation as-
says in semisolid medium, HIPK1-transformed MEFs
formed 2-fold fewer colonies than HIPK1-transformed
MEFs, and 20-fold fewer than p53-transformed MEFs (Fig.
4B and data not shown). Thus, the presence of HIPK1 enhances
malignant transformation by E1ARas.
In primary HIPK1 MEFs and thymocytes, DNA damage
triggered normal p53-dependent cell-cycle arrest and apoptosis
(data not shown). However, when HIPK1-transformed
MEFs were treated with high doses of -irradiation (20 Gy; Fig.
4C), doxorubicin (0.2 gml), or etoposide (1 M) (data not
shown), apoptosis was increased. These results imply that HIPK1
is involved in regulating apoptosis caused by DNA damage in
oncogenically transformed cells.
To investigate whether HIPK1 modulates the transcriptional
activity of p53, we carried out Northern blot analyses of the
expression of the p53-inducible genes Mdm-2, p21, and throm-
bospondin 1 (TSP1) in oncogenically transformed MEFs. As
controls, we used two lines of E1ARas-transformed MEFs
expressing a spontaneous mutation of p53 that were established
in our laboratory; these cells are functionally null for p53. As
expected, basal levels of Mdm2, p21, and TSP-1 transcripts all
Fig. 1. Interaction between p53 and HIPK1. (A) Interaction of HIPK1 with p53
protein in mammalian cells. Myc alone (lane a) or Myc-tagged HIPK1 (lane b)
was transfected into human 293 cells expressing endogenous p53, and cell
lysates were immunoprecipitated with anti-p53 Ab. Immunoprecipitates were
then immunoblotted by using anti-Myc Ab. (B) Deletion analysis of the p53
interaction domain as determined by binding to HIPK1 in a yeast two-hybrid
assay. (C) Deletion analysis of the HIPK1-interaction domain as determined by
binding to p53 in a yeast two-hybrid assay. For B and C, the amino acid
numbers in parentheses indicate the section of p53 or HIPK1 present in the
fusion protein. The double-headed arrow indicates the minimum interaction-
domain required in each case. Shaded areas indicate the sequence-specific
DNA-binding domain of p53 (B) and the kinase domain of HIPK1 (C).
Fig. 2. Northern blot analysis of HIPK1 transcripts in normal and transformed
cells. (A) Northern blot of HIPK1 expression in human tissues. Lanes 1–8 are
heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas,
respectively. (B) HIPK1 expression in various human breast cancer cell lines. N,
normal breast epithelial cells; I, nontumorigenic breast epithelial cell line
(HBL-100). Breast cancer cell lines: ZR75–1, MCF7, BT20-T, DU-475, ZR-75–30,
MDA-MB-361, MDA-MB-231, MDA-MB-468, BT-20, SK-BR-3, T47D, MDA-MB-
231-B3, MDA-MB-231–453, and HS0578T (lanes 1–14).
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were decreased in transformed MEFs expressing mutant p53
compared with transformed MEFs expressing WT p53 (Fig. 5A
Upper). However, in oncogenically transformed HIPK1
MEFs expressing WT p53, basal levels of both Mdm2 transcripts
(Fig. 5A Lower) and protein (Fig. 5B) were decreased, whereas
basal expression of p21 and TSP1 transcripts was unaffected (Fig.
5A Lower). Luciferase reporter assays (see Methods) showed that
the Mdm2 promoter was less active (42.2% of WT value) in
HIPK1-transformed MEFs than in HIPK1-trans-
formed MEFs, whereas the p21 promoter was transactivated to
a similar degree in cells of both genotypes (Fig. 5C). Further-
more, when full-length mouse HIPK1 cDNA was transiently
transfected into HIPK1-transformed MEFs and luciferase
activity was determined, a 4- to 6-fold increase in Mdm2
promoter activation was observed (data not shown). Thus,
expression of the p53 target gene Mdm2 is influenced at the
transcriptional stage by HIPK1.
To confirm that loss of HIPK1 was responsible for the
phenotype of transformed HIPK1 MEFs, we generated
stably transfected ‘‘reintroduced HIPK1 ’’ (re-HIPK1) cell lines
by using the full-length mouse HIPK1 cDNA and Zeocin
selection (see Methods). The reintroduction of HIPK1 into
HIPK1-transformed MEFs increased the expression of
Mdm2 transcripts over that in controls (data not shown) and
restored resistance to doxorubicin and -irradiation (Fig. 6).
To examine the role of HIPK1 in oncogenesis in vivo, mice
were treated with repeated applications of the skin carcinogen
DMBA (22, 23). After 14 weeks, fewer (Fig. 7) and smaller
(Inset) tumors had developed on the skin of treated
HIPK1 mice than on that of heterozygous or WT litter-
mates. Mean tumor numbers were as follows: 1.3 tumors per
HIPK1 mouse (n  13); 4.0 tumors per  mouse (n 
11); and 3.6 tumors per  mouse (n  8). In a second
experiment of 17 weeks, mean tumor numbers were as follows:
1.6 tumors per  mouse (n  10) and 3.0 tumors per 
mouse (n  11). No malignant tumors were found in 23
HIPK1mice examined, although they did arise in WT and
heterozygous mice (28 and 322, respectively) by 15 weeks.
The vast majority of skin tumors were identified as papillomas,
with the remainder diagnosed histologically as keratoacantho-
mas or squamous cell carcinomas (Table 1). These data
indicate that HIPK1 is involved in (at least) malignant squa-
mous cell tumor formation in vivo, and suggest that, like
Mdm2, HIPK1 can promote oncogenesis.
Fig. 3. Autophosphorylation of HIPK1 and in vivo induction of p53 phos-
phorylation by HIPK1. (A) Autoradiograph showing in vitro kinase activity of
HA-tagged murine HIPK1 (HA-HIPK1) using GST-p53 as the substrate. (B)
Tryptic phosphopeptide analysis of p53 isolated from metabolically 32P-
labeled E1ARas transformed HIPK1 and HIPK1 cells. The arrowhead
indicates an additional p53 phosphopeptide present in HIPK1 cells, and
Inset shows the phosphoamino acid composition of this peptide.
Fig. 4. DNA-damage-induced apoptosis in transformed MEFs. (A) Northern
blot analysis of mouse HIPK1 transcripts in E1ARas-transformed MEFs. (B)
Colony formation assay. The mean number  SD of colonies formed in
triplicate experiments by two independent clones each of HIPK1- and
HIPK1-transformed MEFs is shown. (C) Apoptosis of transformed MEFs
induced by -irradiation at the indicated doses. Comparable results for exper-
iments in B and C were obtained in three independent trials.
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Discussion
How might HIPK1 modulate p53 function? In our in vivo assays,
p53 underwent specific serine phosphorylation only when
HIPK1 was present. Serine phosphorylation at specific residues
has been shown to govern p53’s ability to transactivate particular
target genes (24, 25). HIPK1 may itself be phosphorylating p53,
or HIPK1 binding to p53 may facilitate serine phosphorylation
of p53 by another protein kinase. Another possibility is that the
conformation of p53, and thus, its activity might be altered by the
binding of HIPK1. Interaction of p53 with c-Abl (independent of
its kinase activity) has been shown to induce a conformational
change in p53 such that p53 tetramers are stabilized and
DNA-binding activity is enhanced (26).
Kim et al. (11) have suggested that mouse HIPK1 may act as
a transcriptional cofactor (repressor) interacting with the ho-
meoproteins NKx-1.2 and NK-1. We have shown that human
HIPK1 interacts with p53 through a domain that does not
overlap with that which is involved in homeoprotein interaction.
Several other proteins can interact with HIPK1 through its
p53-binding domain (Y.L. and M.D., unpublished data), includ-
ing Hic5 (27), UBC9 (28), and zyxin (29). Interactions with Hic5
and zyxin are particularly interesting because these proteins are
recruited into focal adhesions and provide a link with the
extracellular matrix (focal adhesion complex; refs. 29 and 30).
Interestingly, HIPK1 is expressed at high levels in oncogenically
transformed rat embryonic fibroblasts and MCF7 cells, whereas
Hic5 levels are undetectable. Subsequent analyses of a large
number of tumor and normal cell lines have shown that expres-
sion patterns of HIPK1 and Hic5 are negatively correlated (Y.L.
and M.D., unpublished data). It is possible that, in untrans-
formed cells, HIPK1 is retained in the cytoplasm through its
interactions with focal adhesion proteins such as Hic5. Under
conditions that promote transformation and reduce Hic5 levels,
HIPK1 might be freed to transmigrate to the nucleus, interact
with nuclear p53, and modulate p53-dependent function such
that oncogenesis is enhanced.
Fig. 5. Expression of p53-inducible genes in transformed MEFs. (A) Basal
expression of Mdm2, p21, and TSP-1 transcripts in transformed MEFs. (Upper)
Transformed MEFs expressing either WT or mutant (mt) p53. (Lower) Trans-
formed MEFs either expressing or lacking HIPK1. Comparable results were
obtained by using three other independently generated HIPK1 clones. (B)
Western blot analysis of Mdm2 protein in transformed MEFs. (C) Mdm2
promoter activity. The indicated amounts of pcDNA3.1Zeo plasmids contain-
ing either the control HA sequence (cont) or full-length mouse HIPK1 cDNA
(HIPK1) were electroporated into HIPK1-transformed MEFs. A plasmid
containing the luciferase gene under the control of the Mdm2 promoter was
used as the reporter. Luciferase activity is represented as the fold increase in
transactivation relative to samples transfected with reporter constructs and
control parental plasmids.
Fig. 6. Restoration of apoptosis after stable reintroduction of HIPK1 into
HIPK1-transformed MEFs. pcDNA3.1Zeo plasmids containing either the
control HA sequence or the full-length mouse HIPK1 cDNA were electropo-
rated into HIPK1-transformed MEFs followed by Zeocin selection. Apo-
ptosis of transformed MEFs induced by the indicated doses of doxorubicin or
-irradiation is shown.
Fig. 7. Skin tumor formation in mice treated with DMBA. The back skin of
8-week-old mice was shaved and painted with 10 g of DMBA in 0.2 ml of
acetone once a week for 14 weeks. Tumors in representative organs (including
skin) were scored once a week. The proportions of tumors of various sizes at
14 weeks are shown in Inset. Mean tumor sizes were as follows: 3.1 mm
(HIPK1 mice), 4.2 mm (), and 4.1 mm (). Similar results were
obtained for a second experiment in which mice were treated with DMBA for
17 weeks.
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That HIPK1 may be an oncogene was supported by our
examination of HIPK1-deficient mice. Although HIPK1
mice were phenotypically normal, they were more resistant to
the development of DMBA-induced skin tumors (particularly
benign papillomas) than WT littermates. The loss of HIPK1 also
had a protective effect with respect to malignant progression.
Similarly, in colony-formation assays, HIPK1-transformed
MEF colonies grew more slowly than the equivalent HIPK1
cells. Finally, HIPK1 was up-regulated in tumor cell lines. We
speculate that these differences in malignant progression may
result from differences in downstream events mediated by p53.
Such differences and their relation to HIPK1 warrant future
study.
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Table 1. Distribution of tumor types
HIPK1 genotype Total tumor no.*
Distribution of tumor types
Papillomas Keratoacanthomas Squamous cell carcinomas
 29 24 3 2
 44 37 4 3
 17 14 3 0
*Tumors were scored once a week and histological type was determined in 8 HIPK1, 22 HIPK1, and 23
HIPK1 mice.
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